Committee Composition

  Audit Nominating and Governance Compensation Strategic
John T. Henderson, M.D. Chairman of the Board Independent Director   Member of Nominating and Governance Committee Member of Compensation Committee Committee Chair for Strategic Committee
Lawrence C. Best Independent Director Member of Audit Committee     Member of Strategic Committee
Heiner Dreismann, Ph.D. Independent Director     Committee Chair for Compensation Committee Member of Strategic Committee
Walter Gilbert, Ph.D. Independent Director     Member of Compensation Committee  
Dennis Langer, M.D, J.D. Independent Director Member of Audit Committee Committee Chair for Nominating and Governance Committee    
S. Louise Phanstiel Independent Director Committee Chair for Audit Committee Member of Nominating and Governance Committee    
S. Louise Phanstiel Director

S. Louise Phanstiel joined the Company in September 2009. Ms. Phanstiel held several important positions at WellPoint, Inc. from 1996 to 2007, including President, Specialty Products (2003 to 2007), Senior Vice President, Chief of Staff and Corporate Planning in the Office of the Chairman (2000 to 2003), and Senior Vice President, Chief Accounting Officer, Controller, and Chief Financial Officer for all WellPoint, Inc. subsidiaries, including Blue Cross of California (1996 to 2000). Previously, Ms. Phanstiel was a partner at the international services firm of Coopers and Lybrand where she served clients in life and property/casualty insurance, high technology, and higher education. Ms. Phanstiel formerly served on the Board of Directors of Inveresk Research Group, Inc. and Charles River Laboratories, Inc. Ms. Phanstiel received a B.A. degree in Accounting from Golden Gate University and is a Certified Public Accountant.
Chair of the Board = Chair of the Board Committee Chair = Chair Committee Member = Member Independent Director = Independent Director

Stock transaction information provided by EDGAR Online. Myriad Genetics, Inc. makes no representation or warranty with respect to any of the information contained herein, takes no responsibility for supplementing, updating or correcting any such information and shall have no liability with respect to any such information. This listing does not include derivatives, such as stock option grants or shares purchased through an employee stock purchase plan. For recent transactions, including derivative transactions, see our Section 16 SEC filings page.


Stock Quote (NASDAQ:MYGN)

Price:
36.72
Change:
- 0.34
Open:
37.10
Previous Close:
37.05
Day High:
37.48
Day Low:
36.52
52 Week High:
42.50
52 Week Low:
20.02
Volume:
208,400
12:53 PM ET on Jul 30, 2014
Delayed at least 20 minutes.
Provided by eSignal.

Investor Contact

Scott Gleason
(801) 584-1143
sgleason@myriad.com

Media Contact

Ron Rogers
Corporate Communications and Media Relations
(801) 584-3065
rrogers@myriad.com